Antiangiogenic potential of beta-blockers in the context of juvenile hemangioma treatment

Cover Page

Abstract


Juvenile hemangiomas (JH) — the most common tumor of childhood, which is estimated by various investigators found in 3–10 % of newborns resulting from the local development of significant violations of neoangiogenesis regulation. Research objective: determination of comparative antiangiogenic effectiveness and influence of beta-blockers on the level of a vascular endothelial factor of growth in an experiment. Material and methods. For determination of antiangiogenic effect of beta blockers, comparative studying of their influence on the level of a vascular endothelial factor of growth in an experiment on 72 nonlinear laboratory rats, by average weight 180 ± 20 g which were conditionally divided into 6 groups is executed: 1 — control, 2 — negative control — experimental ischemia (EI, crossing of femoral vessels), 3 — positive control (EI with bevacizumab introduction), 4 — EI with introduction of a timolol, 5 — EI with introduction of a betaksolol, 6 — EI with introduction of interferon alpha 2b. Results. The VEGF levels were: in 1 group — 1.50 ± 0.3 pg/ml, in 2 — 20.3 ± 3.2 pg/ml, 3 — 5.8 ± 0.9 pg/ml, 4 — 13.8 ± 1.4 pg/ml, 5 — 19.2 ± 2.3 pg/ml and 6 — 11.1 ± 2.2 pg/ml. Results of microscopy and immunohistochemical research demonstrate lack of activation of processes of neoangiogenesis in 1 group of animals. At animals of 2nd and 5th groups along with the expressed inflammatory processes the neoangiogenesis phenomena are established. Conclusion. Beta-blockers show the direct or mediated negative impact on synthesis of VEGF and oppression of neoangiogenesis. The activity of selective beta-blocker concerning neoangiogenesis suppression — was lower in comparison by activity non-selective that allows to consider the Timolol effective antiangiogenic remedy.


Vl. V. Dubensky

Tver State Medical University, Ministry of Health of the Russian Federation

Author for correspondence.
Email: tgma.estet@yandex.ru

Russian Federation

Vladislav V. Dubensky — Cand. Sci. (Med.), Assoc. Prof., Prof. of the Department of Dermatovenereology with a Course of Cosmetology

tel.: +7 (961) 016-00-00

V. V. Dubensky

Tver State Medical University, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Russian Federation Valery V. Dubensky — Dr. Sci. (Med.), Prof., Head of the Department of Dermatovenereology with a Course of Cosmetology

  1. Frieden I. J. et al. Infantile hemangiomas: current knowledge, future directions, Proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol. 2005;22:383–406.
  2. Дубенский Вл. В. Этиопатогенез и морфология ювенильных гемангиом. Российский журнал кожных и венерических болезней. 2014;(4):8–12. [Dubensky V. V. Etiopathogenesis and morphology of juvenile hemangiomas. Russian Journal of Skin and Venereal diseases. 2014;(4):8–12. (In Russ.)]
  3. Дубенский Вл. В. Клинико-функциональные особенности ювенильных гемангиом. Современные проблемы дерматовенерологии, иммунологии, косметологии. 2013;(8):15–24. [Dubensky V. V. Clinical and functional features of juvenile hemangiomas. Modern Problems of Dermatovenerology, Immunology, Cosmetology. 2013;(8):15–24. (In Russ.)]
  4. Drolet B., Frieden I. J. Characteristics of infantile hemangiomas as clues to pathogenesis. Does hypoxia connect the dots? Arch Dermatol. 2010;146:1295–1299.
  5. Frieden I. J., Haggstrom A., Drolet B. A. et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol Venereol. 2008;135:860–862.
  6. North P. E., Waner M., Mizeracki A. et al. A unique microvascular phenotype shared by juvenile heamangiomas and human placenta. Arch Dermatol. 2001;137:559–570.
  7. Barnes C. M., Christison-Lagay E. A., Folkman J. The placenta theory and the origin of infantile hemangioma. Lymphat Res Biol. 2007;5(4):245–255.
  8. Hoeger P. H. Infantile Hemangioma: new aspects on the pathogenesis of the most common skin tumour in children. Br J Dermatol. 2011 Feb;164(2):234–235.
  9. Razon M. J., Kraling B. M., Mulliken J. B., Bischoff J. Increase apoptosis coincides with onset of involution in infantile hemangioma. Microcirculation. 1998;5:189–195.
  10. Léauté-Labrèze C., Dumas de la Roque E., Hubiche T., Boralevi F., Thambo J. B., Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–2651 [PubMed].
  11. Drolet B. A., Frommelt P. C., Chamlin S. L., Haggstrom A., Bauman N. M., Chiu Y. E. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–140.
  12. D’Angelo G. et al. cAMP-dependant protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J. Cell Biochem. 1997;67:353–366.
  13. Laccarino G. et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptors overexpression: a novel role for the endothelial adrenergic system. Circ Res. 2005;97:1182–1189.
  14. Тырсина Е. Г., Никулицкий С. И. Роль регуляторной VEGF/ VEGF-R1-системы в опухолевом ангиогенезе (обзор литературы). Онкогинекология. 2015. [Tyrsina E. G., Nikulitsky S. I. The role of the regulatory VEGF/VEGF-R1 system in tumour angiogenesis (literature review). Oncogynecology. 2015. (In Russ.)]
  15. Кукес В. Г., Сычев Д. А., Андреев Д. А. Клиническая фармакология β-адреноблокаторов. РМЖ. 2005;14:932. [Kukes V. G., Sychev D. A., Andreev D. A. Clinical pharmacology of b–adrenoblockers. Breast cancer. Russian Medical Journal. 2005;14:932. (In Russ.)]
  16. Миронов А. Н., Бунатян Н. Д. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К, 2012. 944 с. [Mironov A. N., Bunatyan N. D. Guidelines for conducting preclinical studies of drugs. Moscow: Grif i K, 2012. 944 p. (In Russ.)]
  17. Дубенский В. В., Аун Р. Ю. Эффективность и безопасность применения топического β-адреноблокатора для лечения ювенильных гемангиом. Фарматека. 2018;s1:32–39. [Dubensky V. V., Aun R. Yu. Efficacy and safety of topical β-blocker for the treatment of juvenile hemangiomas. Farmateka. 2018;s1:32–39. (In Russ.)]
  18. Дубенский В. В. Влияние неселективного бета-адреноблокатора на хемотаксис и активную миграцию клеток in vitro в аспекте лечения ювенильных гемангиом. Иммунопатология, аллергология, инфектология. 2016;4:50–59. [Dubensky V. V. Effect of non-selective beta-adrenergic blocker on chemotaxis and in vitro active cell migration in the context of treating juvenile hemangiomas. Immunopathology, Allergology, Infectology. 2016;4:50–59. (In Russ.)]

Views

Abstract - 102

PDF (Russian) - 36

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies